American Society of Plastic Surgeons
For Consumers
 

 Shop Home


 Home  Cart

Product Image

Journal CME Article: Opioid Coprescribing with Sedatives after Implant-Based Breast Reconstruction

Login Required
To add this product to your cart, please log in.

Member Price $25.00Non-Member Price $200.00 In Stock



Product Description

Skeletal muscle relaxants and benzodiazepines are thought to mitigate against postoperative muscle contraction. The Centers for Disease Control and Prevention and the Food and Drug Administration warn against coprescribing them with opioids because of increased risks of overdose and death. The authors evaluated the frequency of coprescribing of opioids with skeletal muscle relaxants or benzodiazepines after implant-based reconstruction.


Faculty
Katherine B. Santosa, M.D., M.S.; Christine S. Wang, M.D.; Hsou-Mei Hu, Ph.D., M.B.A., M.H.S.; Connor R. Mullen, M.D.; Chad M. Brummett, M.D.; Michael J. Englesbe, M.D.; Mark C. Bicket, M.D., Ph.D.; Paige L. Myers, M.D.; Jennifer F. Waljee, M.D., M.P.H., M.S.

Plastic and Reconstruction Surgery®Editors:
Editor-in-Chief: 
Kevin Chung, MD
Co-Editor: Amy Colwell, MD
Section Editors: John Y.S. Kim, MD

Intended Audience
This educational activity is intended for all CME-related persons including plastic surgery practitioners, residents, and other healthcare professionals.

Accreditation
The American Society of Plastic Surgeons (ASPS) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The ASPS designates this enduring material for a maximum of1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
The American Society of Plastic Surgeons (ASPS) requires all faculty, authors, planners, reviewers, managers, staff and other individuals in a position to control or influence the content of an activity to disclose all relevant financial relationships or affiliations. All identified conflicts of interest must be resolved and the educational content thoroughly vetted by ASPS for fair balance, scientific objectivity and appropriateness of patient care recommendations. The ASPS also requires faculty/authors to disclose when off-label/unapproved uses of a product are discussed in a CME activity or included in related materials.

Disclaimer: All relevant financial relationships for planners, faculty, and others in control of content (either individually or as a group) are reviewed by the ASPS Continuing Education Committee and have been mitigated, if applicable.

The following planners/faculty members/reviewers have no relevant financial relationships or affiliations to disclose:
Katherine B. Santosa, M.D., M.S.; Christine S. Wang, M.D.;Hsou-Mei Hu, Ph.D., M.B.A., M.H.S.; Connor R. Mullen, M.D.; Chad M. Brummett, M.D.; Michael J. Englesbe, M.D.; Mark C. Bicket, M.D., Ph.D.; Paige L. Myers, M.D.; Jennifer F. Waljee, M.D., M.P.H., M.S.

AMA PRA Category 1 CreditTM:1.0
Patient Safety Credit: 0.5
Media:Journal Article 
Release Date: 6/01/2023
Expiration Date: 6/01/2026
Estimated time to complete this course:1 hour

*Course access ends on course expiration date

Directly provided by the American Society of Plastic Surgeons (ASPS)

Return Policy for Downloaded and Viewable Products
Products which are downloaded or viewable after purchase may not be returned. By placing an order you are agreeing to the product return terms and conditions set forth by this site. ASPS Shop Return Policy

Product Code: 39094